We are pleased to announce that the COVID-RED study has started last month and already 12,000 participants have been enrolled.
COVID-RED is an Innovative Medicines Initiative (IMI)-funded project which aims to develop an algorithm wherein non-invasively collected markers of human health (temperature, heart rate, heart rate variability) can be used to predict the likelihood of a COVID-19 infection.
The project unites nine organisations from four countries: Ava Women, UCL, VIVE – Det Nationale Forsknings- og Analysecenter for Velfærd, Sanquin, Takeda, Roche, UMC Utrecht, Dr Risch and Julius Clinical. The study will be led by our Chief Scientific Officer Prof. Diederick (Rick) E. Grobbee, MD, PhD, FESC (UMC Utrecht).
For more information about COVID-RED, please visit: https://www.covid-red.eu/